Regenesis Biomedical names new board members
Mr Savas serves as chairman and CEO of Alseres Pharmaceuticals. He holds a bachelor of arts degree in chemistry from Syracuse University. Mr Lunden is a principal with
The US Food and Drug Administration (FDA) has approved Pfizer’s Tukysa (tucatinib) along with pertuzumab and trastuzumab as a maintenance therapy for breast cancer.